Spiropiperidyl rifamycin — narrower CYP3A4 induction than rifampin, used in HIV+TB co-treatment where rifampin would crater PI levels. Still meaningfully induces CYP3A4 (~40% AUC reduction of co-administered substrates).
Half-Life & Elimination Curve (PO: 36h)
Plasma (PO)t½ Decay (36h)
0×t½0h100%(72.9 µg/L)
1×t½36h50%(36.4 µg/L)
2×t½3d25%(18.2 µg/L)
3×t½4.5d12.5%(9.11 µg/L)
4×t½6d6.3%(4.55 µg/L)
5×t½7.5d3.1%(2.28 µg/L)
Elimination t½36h (PO)
Rate Constant (ke)0.0193 h⁻¹
Time to Peak (Tmax)5.28h
Est. Peak (Cmax)72.9 µg/L
Clearance (CL)11.5 L/h
97% Washout (5×t½)7.5d
Dosing Guidelines
Oral (PO): Typical 300 mg (Range: 150–300 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 16% · Volume of Distribution (Vd): 595 L · Absorption (ka): 0.7 h⁻¹ (t½ka ≈ 59m) [PMID 2552902]
Buprenorphine (caution): CYP3A4 induction (weaker than rifampin). McCance-Katz 2011 (PMID:21596492) verbatim: rifabutin "resulted in a significant decrease in buprenorphine plasma concentrations (35% decrease in AUC; p<0.001) no opiate withdrawal was seen". Same paper, head-to-head vs rifampin: rifabutin AUC ↓35%, NO withdrawal; rifampin AUC ↓70%, 50% withdrawal. Rifabutin clinically preferred for HIV/TB + opioid co-therapy. Ratio 0.65 → induction_factor 1.54.